GlassScriptPhysician profile
Farhad Rezvani
NPI 1982796207
$4,897.66
in general payments reported to CMS, 2019-2025
20 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $552 · 2020: $378 · 2021: $539 · 2022: $748 · 2023: $774 · 2024: $737 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623 · Education: $56.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.15 |
| Education | $56.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,184.09 | 2019-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $808.73 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $414.97 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $331.23 | 2020-2025 | Jynarque |
| Amgen INC. | $318.13 | 2019-2025 | Krystexxa, Tavneos |
| Novo Nordisk INC | $301.39 | 2024-2025 | Ozempic, Rybelsus |
| Vifor Pharma, INC. | $299.70 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $185.22 | 2019-2024 | Velphoro |
| Ardelyx, INC. | $173.47 | 2023-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $168.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $133.08 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $125.17 | 2019 | |
| Pfizer INC. | $120.71 | 2019 | |
| Opko Pharmaceuticals, LLC | $91.84 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $83.22 | 2022-2023 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $69.89 | 2024-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $29.09 | 2020 | |
| Cormedix INC. | $23.54 | 2024 | Defencath |
| Ani Pharmaceuticals, INC. | $19.96 | 2023 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $15.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Rezvani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.